Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with SBRT and Chemotherapy in Stage IV Oligometastatic NSCLC
NCT05472467Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Sichuan Cancer Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05472467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472467.